ArticlePakistan journal of medical sciences2025
Efficacy of low-frequency repetitive transcranial magnetic stimulation combined with risperidone in the treatment of schizophrenia patients with auditory verbal hallucinations.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to determine the efficacy and safety of low-frequency (1 Hz) repetitive transcranial magnetic stimulation (rTMS) combined with risperidone in the treatment of schizophrenia patients with auditory verbal hallucinations (AVH). Methodology: This retrospective cohort study was conducted in Wenzhou Seventh People's Hospital and included data from 100 schizophrenia patients with AVH, treated from May 2022 to May 2024. Among them, 50 patients who received low-frequency rTMS combined with risperidone were matched with the cohort of patients who received risperidone alone in a ratio of 1:1. The scores of the Psychotic Symptom Rating Scale (PSYRATS), Auditory Hallucination Rating Scale (AHRS) and Positive and Negative Syndrome Scale (PANNS) were compared between the two groups at baseline, at the end of treatment (five weeks) and after one month of follow-up. Results: PSYRATS, AHRS, and PANSS scores of the two groups decreased with time (p<0.05). After treatment, the general psychopathological symptoms, positive symptom scores, and PANSS total scores of the rTMS/risperidone group were lower than those of the risperidone group (p < 0.05). There was no difference between the two groups at one-month follow-up (p > 0.05). The incidence of adverse reactions during treatment was comparable in the two groups (p > 0.05). Conclusions: The results of this study showed that risperidone, combined with 1Hz rTMS, showed no benefit in improving the auditory hallucination symptoms of schizophrenia patients with AVH. However, the combined regimen could significantly improve the positive symptom scores of patients during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.